PeptideStack
5.2kquestions
20kanswers
220users

Is a 97.9% result from Medutest comparable to 96.4% from PeptideMeter?

Asked 3 Sept 2025Modified 7 months agoViewed 24k times
21

Stated plainly: 97.9% · Medutest · 96.4% · PeptideMeter.

I suspect the honest answer is that it depends, in which case I would like to know on what.

Assume I can obtain either option without difficulty, so availability is not the deciding factor.

Is there a defensible reason to prefer one, or is this a coin flip?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
PH
askedpetra_hovland42k383 Sept 2025

5 Answers

Sorted by votes
58

In practice, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Specifically, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
BN
answeredbridget_nyathi16k1713 Oct 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
38

Put another way, the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
LS
answeredlow_dead_space42k388 Oct 2025
5Good answer, but the confidence interval in the cited trial is wider than implied. – Dr_Lena_Ostrowska 4 months ago
add a comment
31

More usefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Specifically, gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 30 Oct 2025 by g_paskevicius — added the method parameters

shareimprove this answerflag
GP
answeredg_paskevicius44k3820 Oct 2025
8This should probably be in the site help pages rather than buried in an answer. – tobias_maartens 8 months ago
7Good answer, but the confidence interval in the cited trial is wider than implied. – Dr_Fatima_Belkacem 7 months ago
add a comment
24

Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
IB
answeredines_brandt93k24831 Oct 2025
2Adding for future readers: the certificate should carry the lot number, not just a batch code. – tandem_gradient 7 months ago
add a comment
22

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir46k3828 Dec 2025
2Thank you — the worked example is what makes this usable. – deamidation_watch 7 months ago
Related: the same reasoning applies to the counter-ion question. – Dr_Lena_Ostrowska 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.